Trials / Terminated
TerminatedNCT02985021
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Seattle Institute for Biomedical and Clinical Research · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
Detailed description
This is a phase 2 study of the combination of docetaxel and carboplatin in patients with germline inactivation of genes in the homologous recombination pathway, including BRCA1, BRCA2, and Ataxia Telangiectasia Mutated (ATM). PRIMARY OBJECTIVE To assess rate of 50% Prostate Specific Androgen (PSA) decline to docetaxel and carboplatin
Conditions
- Hormone-Resistant Prostate Cancer
- Metastatic Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | Chemotherapy |
| DRUG | Docetaxel | Chemotherapy |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
- First posted
- 2016-12-07
- Last updated
- 2021-08-05
- Results posted
- 2021-08-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02985021. Inclusion in this directory is not an endorsement.